Harrow Completes Acquisition of Tyrvaya Nasal Spray From Viatris

approvedTyrvayaPositive

AI Analysis

Summary

Harrow has completed its acquisition of Tyrvaya nasal spray from Viatris. The transaction represents a product acquisition in the specialty pharmaceutical space.

Outcome Details

Harrow completed acquisition of Tyrvaya nasal spray from Viatris

Importance:6/10

Sentiment:

0.60

M&Aacquisitionproduct acquisitionnasal spray

Related Companies

$VTRS

Read the original article

Published by yahoo_finance on October 5, 2026 12:10 PM

Read Original